Automated page speed optimizations for fast site performance
Qualified participants may receive compensation after every blood draw.
Cytomegalovirus, shortened to CMV, is a leading cause of birth defects around the world. CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people.
If a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to suffer long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against CMV.
The total length of participation in this clinical trial is
approximately 2½ years (30 months).
Each participant has a 50% chance of receiving the investigational vaccine and a 50% chance of receiving a placebo—like flipping a coin.
Our team will contact you to verify your eligiblity and answer any questions you may have.
Our team will contact you to verify your eligiblity and answer any questions you may have.